Swedish Orphan International, Strada Quarta 6/1 D – 43123 Parma (PR)
(from 23/02/2009 to 31/03/2013 = 4 years and one month)
In the TA (Therapeutic Area) «inflammation/rheumatology»:
Marketing strategy development (and implementation in collaboration with international business partners) for the brand KINERET™ (anakinra), a recombinant human Interleukin-1 receptor antagonist (IL-1Ra), initially approved for the treatment of Rheumatoid arthritis, but due to its striking effectiveness also frequently used off-label for the treatment of IL-1 mediated, autoinflammatory diseases, such as CAPS (Cryopyrin-Associated Periodic Syndrome); TRAPS (Tumor Necrosis Factor Receptor Associated Periodic Syndrome); SJIA (Systemic Juvenile Idiopathic Arthritis); AoSD (Adult onset Still’s Disease) – KINERET™ (anakinra) later gathered approval for the treatment of some these disorders
